VIL1 and microvillus inclusion disease: To compare the treatment efficacy between MYO5B knockout and the MYO5B point mutation at G519R, which has been identified in a patient with MVID (7), Vil1-CreERT2;Myo5bflox/G519R [MYO5B(G519R)] mice were treated with tamoxifen and Compound-1 in the same manner.